Dissolution and bracketing (EMA) [Regulatives / Guidelines]

posted by wienui  – Germany/Oman, 2020-04-04 10:42 (1035 d 07:26 ago) – Posting: # 21315
Views: 1,887

Hi Susan,

All the General biowaiver criteria are fulfilled except the f2 similarity is not achieved between the highest strength (used in BE study) and the lower strengths


I see from your post above that you had tried to use same dose comparison (2 x 5 mg vs 10 mg), but it didn't help.

❝ Do I need to do a BE study on all the strengths that are not showing similarity in dissolution


No you don't need if you intended to use the bracketing approach.

What about the similarity in dissolution between the lower strengths for which BE were not conducted, are They similar or there were dissolution differences?

If there are similar between each others, then as you mentioned just perform one BE study for the strength differing most in dissolution with the highest strength (EMA).

In your place I will try to take EMA scientific advice, but you have to keep in mind that any scientific advice or protocol assistance given is not legally binding with regard to any future marketing authorisation application of the product concerned, either on the Agency/CHMP/COMP, or on the Applicant.

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
22,478 posts in 4,708 threads, 1,604 registered users;
19 visitors (0 registered, 19 guests [including 12 identified bots]).
Forum time: 17:08 CET (Europe/Vienna)

Learning of many things
does not teach intelligence.    Heraclitus of Ephesus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5